EyePoint Pharmaceuticals Inc. buy JPMorgan Chase & Co.
Start price
22.01.24
/
50%
€21.60
Target price
22.01.25
€32.12
Performance (%)
-27.64%
Price
26.04.24
€15.63
Summary
This prediction is currently active. The price of EyePoint Pharmaceuticals Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -27.64%. This prediction currently runs until 22.01.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| EyePoint Pharmaceuticals Inc. | 1.494% | 1.494% |
| iShares Core DAX® | -0.992% | -3.231% |
| iShares Nasdaq 100 | -0.225% | -3.339% |
| iShares Nikkei 225® | -0.736% | -7.859% |
| iShares S&P 500 | -0.509% | -2.979% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread EyePoint Pharmaceuticals Inc. diskutieren
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $35.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat